Literature DB >> 16585195

The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha.

Frédéric Dayan1, Danièle Roux, M Christiane Brahimi-Horn, Jacques Pouyssegur, Nathalie M Mazure.   

Abstract

The function of the hypoxia-inducible factor-1 (HIF-1), the key transcription factor involved in cellular adaptation to hypoxia, is restricted to low oxygen tension (pO(2)). As such, this transcription factor is central in modulating the tumor microenvironment, sensing nutrient availability, and controlling anaerobic glycolysis, intracellular pH, and cell survival. Degradation and inhibition of the limiting HIF-1alpha subunit are intimately connected in normoxia. Hydroxylation of two proline residues by prolyl hydroxylase domain (PHD) 2 protein earmarks the protein for degradation, whereas hydroxylation of an asparagine residue by factor-inhibiting HIF-1 (FIH-1 or FIH) reduces its transcriptional activity. Indeed, silencing of either PHD2 or FIH in normoxia partially induced hypoxic genes, whereas combined PHD2/FIH silencing generated a full hypoxic gene response. Given the fact that HIF-1alpha possesses two transcriptional activation domains [TAD; NH(2)-terminal (N-TAD) and COOH-terminal (C-TAD)], we hypothesized on a possible bifunctional activity of HIF-1alpha that could be discriminated by FIH, an inhibitor of the C-TAD. In human cell lines engineered to overexpress or silence FIH in response to tetracycline, we show by quantitative reverse transcription-PCR that a set of hypoxic genes (ca9, phd3, pgk1, and bnip3) respond differently toward FIH expression. This finding, extended to 26 hypoxia-induced genes, indicates differential gene expression by the N-TAD and C-TAD in response to the hypoxic gradient. We propose that the oxygen-sensitive attenuator FIH, together with two distinct TADs, is central in setting the gene expression repertoire dictated by the cell pO(2).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585195     DOI: 10.1158/0008-5472.CAN-05-4564

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  92 in total

1.  Transglutaminase 2 protects against ischemic stroke.

Authors:  A J Filiano; J Tucholski; P J Dolan; G Colak; G V W Johnson
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

2.  GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α.

Authors:  J Chiche; S Pommier; M Beneteau; L Mondragón; O Meynet; B Zunino; A Mouchotte; E Verhoeyen; M Guyot; G Pagès; N Mounier; V Imbert; P Colosetti; D Goncalvès; S Marchetti; J Brière; M Carles; C Thieblemont; J-E Ricci
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

3.  Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Authors:  Charline Ladroue; David Hoogewijs; Sophie Gad; Romain Carcenac; Federica Storti; Michel Barrois; Anne-Paule Gimenez-Roqueplo; Michel Leporrier; Nicole Casadevall; Olivier Hermine; Jean-Jacques Kiladjian; André Baruchel; Fadi Fakhoury; Brigitte Bressac-de Paillerets; Jean Feunteun; Nathalie Mazure; Jacques Pouysségur; Roland H Wenger; Stéphane Richard; Betty Gardie
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

4.  The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.

Authors:  Qin Yan; Steven Bartz; Mao Mao; Lianjie Li; William G Kaelin
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

Review 5.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

6.  The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line.

Authors:  Chen Li; Hye-Yeung Kim; Huy Vuong; Tasneem Patwa; Manoj Pal; Randall E Brand; Diane M Simeone; David M Lubman
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 7.  The hypoxia-inflammation link and potential drug targets.

Authors:  Michael Koeppen; Tobias Eckle; Holger K Eltzschig
Journal:  Curr Opin Anaesthesiol       Date:  2011-08       Impact factor: 2.706

Review 8.  Molecular responses to hypoxia-inducible factor 1α and beyond.

Authors:  Jason Brocato; Yana Chervona; Max Costa
Journal:  Mol Pharmacol       Date:  2014-02-25       Impact factor: 4.436

9.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 10.  Ion channels: functional expression and therapeutic potential in cancer. Colloquium on Ion Channels and Cancer.

Authors:  Scott P Fraser; Luis A Pardo
Journal:  EMBO Rep       Date:  2008-05-02       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.